Current Construction of Monitoring and Evaluation System of Adverse Drug Reactions in Anhui Province

doi:10.19803/j.1672-8629.2019.12.04

Abstract

Abstract: Objective To investigate the status quo of the construction of ADR monitoring and evaluation systems at the grass-roots level, analyze the main problems, and explore the countermeasures. Methods Questionnaires were used to investigate the construction of ADR monitoring organization, staffing, monitoring personnel and monitoring networks in Anhui Province. Results In Anhui Province, only provincial centers and four cities had independent monitoring agencies, while twelve cities and one hundred and five counties (districts) did not. Part-time monitors in monitoring institutions of cities, counties (districts) and health care professionals accounted for 70.3% and 46.9% respectively. Conclusion The grass-roots ADR monitoring institutions and personnel cannot meet the needs of ADR monitoring under new circumstances. It is urgent to strengthen the construction of ADR monitoring and evaluation systems at grass-roots levels.

Key words: adverse drug reactions, monitoring system construction, investigation, suggestions

CLC Number:

R994.11

HONG Wei, WANG Feng. Current Construction of Monitoring and Evaluation System of Adverse Drug Reactions in Anhui Province[J]. Chinese Journal of Pharmacovigilance, 2019, 16(12): 722-726.

References

[1] 徐晓娣. 国内外不同主体对药品不良反应报告的认知、态度与实践研究综述[J]. 中国药物警戒, 2019, 16(4):239-243.
[2] 葛楠,罗兴洪.我国药物警戒体系建设的发展与未来[J].中国食品药品监管, 2019, 2(181):21-25.
[3] 桑媛, 吴世福, 路长飞, 等. 检查视角下生产企业药品不良反应报告与监测的问题及思考[J]. 中国药物警戒, 2019,16(4): 215-218.
[4] 刘贵银,孔佑华,冯华东.基层药品不良反应监测报告现状及评价难点分析[J].中国药物警戒. 2011 , 8(9):538-539.
[5] 金锋,曲毅,樊若曦,等.全国省级药品不良反应监测机构建设现状研究及对策[J].中国药物警戒. 2015, 12(4):224-228.
[6] 张慧霞,刘超,陈建玉,等.浅谈监管部门在药物警戒和药品风险管理中的地位与责任[J].中国药物警戒, 2009,6(2):69-73.
[7] 胡文俊,蔡吉芬. 我国药品不良反应报告与监测现状分析[J].中国药物警戒, 2012, 9(2):94-94.
[8] 付文,杜娟,王继堃,等.试论我国医疗机构在药物警戒中的作用[J].中国药物警戒, 2009, 6(4):193-197.
[9] 张桂菊,初晓艺,田月洁,等.欧盟药物警戒体系对我国的启示[J].中国药物警戒, 2015, 12(10):593-596.
[10] 卢玉美. 印度药物警戒系统概述[J].中国药物警戒, 2012,9(7):413-417.
[11] 王丹,董铎. 药品上市许可持有人直接报告不良反应制度探讨[J]. 中国药物警戒, 2018, 15(11): 648-651.
[12] 彭丽丽,沈璐,董铎,等.浅析国外药物警戒受权人制度对我国药品不良反应监测工作的启示[J].中国药物警戒, 2015, 12(2):89-91.
[13] 余永红,陈光建,陈希.湖南省基层药品不良反应监测哨点调查研究[J].中国药物警戒, 2011, 8(8):489-491.
[14] 王涛,王丹,董铎.构建中国药物警戒体系的思考[J].中国食品药品监管, 2019, 1(180):37-41.
[15] 边博洋,常峰,邵蓉.美国药品安全风险管理最终指南对我国药品安全风险管理的启示[J].中国药事, 2007,21(12):956-959.
[16] 董铎,吴桂枝,程刚. 欧盟新法规下的药物警戒制度简介[J].中国药物警戒, 2012, 9(11):662-665.
[17] 李泮海,冯巧巧,田月洁.基层药物警戒体系建设和科学发展[J].中国药物警戒, 2010, 7(9):536-639.